9COO image
Entry Detail
PDB ID:
9COO
EMDB ID:
Keywords:
Title:
Nanobody 4 bound to Apolipoprotein B 100
Biological Source:
PDB Version:
Deposition Date:
2024-07-17
Release Date:
2024-12-25
Method Details:
Experimental Method:
Resolution:
3.73 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Apolipoprotein B 100
Chain IDs:A
Chain Length:4563
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Maltodextrin-binding protein,Immunoglobulin G-binding protein A,Immunoglobulin G-binding protein G
Chain IDs:B
Chain Length:545
Number of Molecules:1
Biological Source:Escherichia coli
Polymer Type:polypeptide(L)
Description:Legobody 8D3 Fab Heavy Chain
Chain IDs:C (auth: H)
Chain Length:234
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:Legobody 8D3 Fab Light Chain
Chain IDs:D (auth: L)
Chain Length:219
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Description:ApoB100 nanobody 4
Chain IDs:E (auth: N)
Chain Length:131
Number of Molecules:1
Biological Source:Camelus bactrianus
Polymer Type:polypeptide(L)
Description:Low-density lipoprotein receptor
Chain IDs:F (auth: R)
Chain Length:795
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor.
Nature 638 829 835 (2025)
PMID: 39663455 DOI: 10.1038/s41586-024-08223-0

Abstact

Apolipoprotein B100 (apoB100) is a structural component of low-density lipoprotein (LDL) and a ligand for the LDL receptor (LDLR)1. Mutations in apoB100 or in LDLR cause familial hypercholesterolaemia, an autosomal dominant disease that is characterized by a marked increase in LDL cholesterol (LDL-C) and a higher risk of cardiovascular disease2. The structure of apoB100 on LDL and its interaction with LDLR are poorly understood. Here we present the cryo-electron microscopy structures of apoB100 on LDL bound to the LDLR and a nanobody complex, which can form a C2-symmetric, higher-order complex. Using local refinement, we determined high-resolution structures of the interfaces between apoB100 and LDLR. One binding interface is formed between several small-ligand-binding modules of LDLR and a series of basic patches that are scattered along a β-belt formed by apoB100, encircling LDL. The other binding interface is formed between the β-propeller domain of LDLR and the N-terminal domain of apoB100. Our results reveal how both interfaces are involved in LDL dimer formation, and how LDLR cycles between LDL- and self-bound conformations. In addition, known mutations in either apoB100 or LDLR, associated with high levels of LDL-C, are located at the LDL-LDLR interface.

Legend

Protein

Chemical

Disease

Primary Citation of related structures